<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00254163</url>
  </required_header>
  <id_info>
    <org_study_id>03017</org_study_id>
    <secondary_id>NIP-03-007</secondary_id>
    <nct_id>NCT00254163</nct_id>
  </id_info>
  <brief_title>Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients</brief_title>
  <official_title>A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-cell Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US Oncology Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astex Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>US Oncology Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to find out what effects (good and bad) the combination
      of Nipent+Cytoxan+Rituxan has on CLL cancer compared to Fludara+Cytoxan+Rituxan. While all of
      these drugs are approved by the Food and Drug Administration (FDA) for the treatment of other
      cancers, these combinations are experimental for the treatment of CLL.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infection Rate</measure>
    <time_frame>6 cycles of 28-day for FCR and 8 cycles of 21-day for PCR, or until PD, CR, or intolerable toxicity</time_frame>
    <description>infection=febrile events requiring treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infective Event Rate</measure>
    <time_frame>6 cycles of 28-day for FCR and 8 cycles of 21-day for PCR, or until PD, CR, or intolerable toxicity</time_frame>
    <description>infective events=temperature &gt;101 without symptoms or temp &lt;101 with symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Hospitalized</measure>
    <time_frame>6 cycles of 28-day for FCR and 8 cycles of 21-day for PCR, or until PD, CR, or intolerable toxicity</time_frame>
    <description>Percentage of patients who were hospitalized due to any reasons during the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic Recovery</measure>
    <time_frame>2 months post-treatment</time_frame>
    <description>defined as Hb &gt;11g/dL and a platelet count &gt;100 × 10^3/mm^3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Neutrophil Count (ANC) at Post-treatment</measure>
    <time_frame>2 months post-treatment</time_frame>
    <description>mean Absolute Neutrophil Count (ANC) measured 2 months (8-10 weeks) following the last dose of study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Remission (CR)</measure>
    <time_frame>6 cycles of 28-day for FCR and 8 cycles of 21-day for PCR, or until PD, CR, or intolerable toxicity</time_frame>
    <description>Definitions of response is evaluated using guidelines proposed by the National Cancer Institute-Sponsored Working Group for Chronic Lymphocytic Leukemia.
Complete remission (CR) requires all of the following for a period of at least 2 months:
Absence of lymphadenopathy by physical examination and appropriate radiographic techniques. Lymph nodes must be &lt;1 cm.
No evidence of hepatomegaly or splenomegaly.
Absence of constitutional symptoms.
Normal CBC as exhibited by:
Polymorphonuclear leukocytes ≥ 1,500/mm^3
Platelets &gt; 100,000/mm^3
Hemoglobin &gt; 11.0 g/dL (untransfused)
Bone marrow aspirate and biopsy should be performed 2 months after clinical and laboratory results demonstrate that all of the requirements listed in 1-4 have been met to demonstrate that a CR has been achieved. The marrow sample must be at least normocellular for age, with less than 30% of the nucleated cells being lymphocytes.
Lymphoid nodules should be absent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Remission Rate (ORR)</measure>
    <time_frame>6 cycles of 28-day for FCR and 8 cycles of 21-day for PCR, or until PD, CR, or intolerable toxicity</time_frame>
    <description>Complete remission (CR) see Outcome Measure 6. Partial remission (PR) must exhibit criteria 1 and 2 as well as one or more of the remaining features for at least 2 months.
≥50% decrease in peripheral blood lymphocyte count from the pretreatment baseline value.
≥50% reduction in lymphadenopathy.
≥50% reduction in the size of the liver and/or spleen.
Polymorphonuclear leukocytes ≥ 1,500/mm^3 or 50% improvement over baseline.
Platelets &gt;100,000/mm^3 or 50% improvement over baseline.
Hemoglobin &gt;11.0 g/dL or 50% improvement over baseline without transfusions. Nodular partial remission (nPR) is defined as a CR with persistent bone marrow nodules; Objective Remission (OR) = CR + PR + nPR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) Rate at 1-year</measure>
    <time_frame>12 months after registered.</time_frame>
    <description>PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) Rate at 2-year</measure>
    <time_frame>24 months after registered.</time_frame>
    <description>PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>B-Cell Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Fludarabine, Cyclophosphamide, and Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fludarabine, Cyclophosphamide, and Rituximab (dosage based on day in cycle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pentostatin, Cyclophosphamide, and Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pentostatin, Cyclophosphamide, and Rituximab (dosage depends on day in cycle)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <arm_group_label>Fludarabine, Cyclophosphamide, and Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Fludarabine, Cyclophosphamide, and Rituximab</arm_group_label>
    <arm_group_label>Pentostatin, Cyclophosphamide, and Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Fludarabine, Cyclophosphamide, and Rituximab</arm_group_label>
    <arm_group_label>Pentostatin, Cyclophosphamide, and Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentostatin</intervention_name>
    <arm_group_label>Pentostatin, Cyclophosphamide, and Rituximab</arm_group_label>
    <other_name>Nipent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

        Patients will be eligible for inclusion in this study if they meet all of the following
        criteria:

          -  Progressive, histologically proven B-cell CLL.

          -  Stage II, III, or IV B-cell CLL, as defined by Appendix III.

        Note: The pathology or flow cytometry (of peripheral blood or a bone marrow) report, done
        by the local laboratory which documents these findings, must be included in the source
        documents. The SI must review the above pathology report or flow cytometry report results
        (including bone marrow aspirate analysis and CD5 and CD20 results) by fax, prior to
        registration, to confirm each patient's eligibility. Results should be consistent with
        typical B-cell CLL. If Dr. Reynolds is not available to review these documents, they must
        be reviewed by Dr. Nicholas J. Di Bella.

          -  Patient must be CD20 +

          -  Patient must be CD5+ (CD5 &gt;70%)

          -  No more than 1 prior course (regimen) of chemotherapy, which can include Fludara or
             Rituxan

          -  No prior radiation therapy, except for the treatment of skin cancer or a nonmalignant
             condition.

          -  If patient has lymph node involvement, a CT scan confirming measurable tumor size
             (lymph node must be &gt;1 cm in its longest transverse diameter).

          -  SI has been notified IF patient is on replacement steroids at time of registration.

          -  Age greater than 18 years.

          -  ECOG performance status of 0-2 (Appendix I).

          -  Normal renal function (creatinine &lt;1.5 mg/dL and BUN &lt;25 mg/dL).

          -  Absolute neutrophil count (ANC) greater than 1,000 cells/µL, platelet count greater
             than 50,000 cells/µL, and hemoglobin greater than 9 g/dL.

          -  Bilirubin less than 2.0 mg/dL, and AST and ALT less than 5 times the upper limit of
             normal.

          -  Negative serum pregnancy test within 7 days prior to registration (female patients of
             childbearing potential).

          -  Agrees to use an acceptable method of birth control, if fertile patient (male or
             female), to avoid pregnancy for the duration of the study and for at least 3 months
             thereafter.

          -  A signed Patient Informed Consent Form has been obtained.

          -  A signed Patient Authorization Form has been obtained.

        EXCLUSION CRITERIA:

        Patients will be excluded from this study if they meet any of the following criteria:

          -  Any disease other than histologically confirmed progressive, Stage II, III, or IV CLL.

          -  Well differentiated lymphocytic lymphoma in nodes without lymphocytosis.

          -  More than 1 prior course (regimen) of chemotherapy.

          -  Any radiation for the treatment of CLL.

          -  Any prior Nipent.

          -  Known to be CD20 negative (CD20 &lt;20%).

          -  Pregnant or lactating, or has a positive pregnancy test.

          -  Has a history of other malignancy (other than in situ cervical cancer, carcinoma
             intraepithelial neoplasia, or non-melanoma skin cancer) within the last 5 years, which
             could affect the administration of these study drugs or assessment of current CLL.

          -  Known to be HIV positive.

          -  Uncontrolled thyroid disease or uncontrolled abnormal thyroid function.

        Note: Patients with thyroid disease that is controlled with medication may participate.

          -  A history of recent, unstable organic heart disease or stable organic heart disease
             with LVEF &lt;50%.

          -  A known hypersensitivity to Fludara, Nipent, Rituxan, or Cytoxan, or any component of
             these drugs.

          -  Autoimmune hemolytic anemia.

          -  Unable to comply with requirements of study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Reynolds, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>US Oncology Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Centers of Florida, P.A.</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Center</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Hematology Oncology PA</name>
      <address>
        <city>Westminster</city>
        <state>Maryland</state>
        <zip>21157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph Oncology, Inc</name>
      <address>
        <city>St Joseph</city>
        <state>Missouri</state>
        <zip>64507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, PC</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Carolina Oncology Hemato</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Cancer Center-McAllen</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Cancer Center-Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest-South</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Mem Hosp/North Star Lodge</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2005</study_first_submitted>
  <study_first_submitted_qc>November 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <results_first_submitted>February 2, 2016</results_first_submitted>
  <results_first_submitted_qc>September 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 3, 2016</results_first_posted>
  <last_update_submitted>September 15, 2016</last_update_submitted>
  <last_update_submitted_qc>September 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Pentostatin</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FCR Arm</title>
          <description>Fludarabine, Cyclophosphamide, and Rituximab</description>
        </group>
        <group group_id="P2">
          <title>PCR Arm</title>
          <description>Pentostatin, Cyclophosphamide, and Rituximab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient request/withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator request</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed entry</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT population</population>
      <group_list>
        <group group_id="B1">
          <title>FCR Arm</title>
          <description>Fludarabine, Cyclophosphamide, and Rituximab</description>
        </group>
        <group group_id="B2">
          <title>PCR Arm</title>
          <description>Pentostatin, Cyclophosphamide, and Rituximab</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="92"/>
            <count group_id="B2" value="92"/>
            <count group_id="B3" value="184"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.3" spread="10.2"/>
                    <measurement group_id="B2" value="63.6" spread="9.9"/>
                    <measurement group_id="B3" value="63.5" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed: Black/Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Infection Rate</title>
        <description>infection=febrile events requiring treatment</description>
        <time_frame>6 cycles of 28-day for FCR and 8 cycles of 21-day for PCR, or until PD, CR, or intolerable toxicity</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>FCR Arm</title>
            <description>Fludarabine, Cyclophosphamide, and Rituximab</description>
          </group>
          <group group_id="O2">
            <title>PCR Arm</title>
            <description>Pentostatin, Cyclophosphamide, and Rituximab</description>
          </group>
        </group_list>
        <measure>
          <title>Infection Rate</title>
          <description>infection=febrile events requiring treatment</description>
          <population>Per protocol population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4" lower_limit="21.8" upper_limit="42.3"/>
                    <measurement group_id="O2" value="36.5" lower_limit="26.3" upper_limit="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infective Event Rate</title>
        <description>infective events=temperature &gt;101 without symptoms or temp &lt;101 with symptoms</description>
        <time_frame>6 cycles of 28-day for FCR and 8 cycles of 21-day for PCR, or until PD, CR, or intolerable toxicity</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>FCR Arm</title>
            <description>Fludarabine, Cyclophosphamide, and Rituximab</description>
          </group>
          <group group_id="O2">
            <title>PCR Arm</title>
            <description>Pentostatin, Cyclophosphamide, and Rituximab</description>
          </group>
        </group_list>
        <measure>
          <title>Infective Event Rate</title>
          <description>infective events=temperature &gt;101 without symptoms or temp &lt;101 with symptoms</description>
          <population>Per protocol population</population>
          <units>percentage of infective events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Hospitalized</title>
        <description>Percentage of patients who were hospitalized due to any reasons during the study period.</description>
        <time_frame>6 cycles of 28-day for FCR and 8 cycles of 21-day for PCR, or until PD, CR, or intolerable toxicity</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>FCR Arm</title>
            <description>Fludarabine, Cyclophosphamide, and Rituximab</description>
          </group>
          <group group_id="O2">
            <title>PCR Arm</title>
            <description>Pentostatin, Cyclophosphamide, and Rituximab</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Hospitalized</title>
          <description>Percentage of patients who were hospitalized due to any reasons during the study period.</description>
          <population>Per protocol population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematologic Recovery</title>
        <description>defined as Hb &gt;11g/dL and a platelet count &gt;100 × 10^3/mm^3</description>
        <time_frame>2 months post-treatment</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>FCR Arm</title>
            <description>Fludarabine, Cyclophosphamide, and Rituximab</description>
          </group>
          <group group_id="O2">
            <title>PCR Arm</title>
            <description>Pentostatin, Cyclophosphamide, and Rituximab</description>
          </group>
        </group_list>
        <measure>
          <title>Hematologic Recovery</title>
          <description>defined as Hb &gt;11g/dL and a platelet count &gt;100 × 10^3/mm^3</description>
          <population>Per protocol population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0.7" upper_limit="9.9"/>
                    <measurement group_id="O2" value="14.1" lower_limit="7.5" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absolute Neutrophil Count (ANC) at Post-treatment</title>
        <description>mean Absolute Neutrophil Count (ANC) measured 2 months (8-10 weeks) following the last dose of study treatment</description>
        <time_frame>2 months post-treatment</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>FCR Arm</title>
            <description>Fludarabine, Cyclophosphamide, and Rituximab</description>
          </group>
          <group group_id="O2">
            <title>PCR Arm</title>
            <description>Pentostatin, Cyclophosphamide, and Rituximab</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Neutrophil Count (ANC) at Post-treatment</title>
          <description>mean Absolute Neutrophil Count (ANC) measured 2 months (8-10 weeks) following the last dose of study treatment</description>
          <population>Per protocol population</population>
          <units>10^3 cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.9"/>
                    <measurement group_id="O2" value="2.2" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Remission (CR)</title>
        <description>Definitions of response is evaluated using guidelines proposed by the National Cancer Institute-Sponsored Working Group for Chronic Lymphocytic Leukemia.
Complete remission (CR) requires all of the following for a period of at least 2 months:
Absence of lymphadenopathy by physical examination and appropriate radiographic techniques. Lymph nodes must be &lt;1 cm.
No evidence of hepatomegaly or splenomegaly.
Absence of constitutional symptoms.
Normal CBC as exhibited by:
Polymorphonuclear leukocytes ≥ 1,500/mm^3
Platelets &gt; 100,000/mm^3
Hemoglobin &gt; 11.0 g/dL (untransfused)
Bone marrow aspirate and biopsy should be performed 2 months after clinical and laboratory results demonstrate that all of the requirements listed in 1-4 have been met to demonstrate that a CR has been achieved. The marrow sample must be at least normocellular for age, with less than 30% of the nucleated cells being lymphocytes.
Lymphoid nodules should be absent.</description>
        <time_frame>6 cycles of 28-day for FCR and 8 cycles of 21-day for PCR, or until PD, CR, or intolerable toxicity</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>FCR Arm</title>
            <description>Fludarabine, Cyclophosphamide, and Rituximab</description>
          </group>
          <group group_id="O2">
            <title>PCR Arm</title>
            <description>Pentostatin, Cyclophosphamide, and Rituximab</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Remission (CR)</title>
          <description>Definitions of response is evaluated using guidelines proposed by the National Cancer Institute-Sponsored Working Group for Chronic Lymphocytic Leukemia.
Complete remission (CR) requires all of the following for a period of at least 2 months:
Absence of lymphadenopathy by physical examination and appropriate radiographic techniques. Lymph nodes must be &lt;1 cm.
No evidence of hepatomegaly or splenomegaly.
Absence of constitutional symptoms.
Normal CBC as exhibited by:
Polymorphonuclear leukocytes ≥ 1,500/mm^3
Platelets &gt; 100,000/mm^3
Hemoglobin &gt; 11.0 g/dL (untransfused)
Bone marrow aspirate and biopsy should be performed 2 months after clinical and laboratory results demonstrate that all of the requirements listed in 1-4 have been met to demonstrate that a CR has been achieved. The marrow sample must be at least normocellular for age, with less than 30% of the nucleated cells being lymphocytes.
Lymphoid nodules should be absent.</description>
          <population>Per protocol population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="7.4" upper_limit="23.1"/>
                    <measurement group_id="O2" value="7.1" lower_limit="2.6" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Remission Rate (ORR)</title>
        <description>Complete remission (CR) see Outcome Measure 6. Partial remission (PR) must exhibit criteria 1 and 2 as well as one or more of the remaining features for at least 2 months.
≥50% decrease in peripheral blood lymphocyte count from the pretreatment baseline value.
≥50% reduction in lymphadenopathy.
≥50% reduction in the size of the liver and/or spleen.
Polymorphonuclear leukocytes ≥ 1,500/mm^3 or 50% improvement over baseline.
Platelets &gt;100,000/mm^3 or 50% improvement over baseline.
Hemoglobin &gt;11.0 g/dL or 50% improvement over baseline without transfusions. Nodular partial remission (nPR) is defined as a CR with persistent bone marrow nodules; Objective Remission (OR) = CR + PR + nPR.</description>
        <time_frame>6 cycles of 28-day for FCR and 8 cycles of 21-day for PCR, or until PD, CR, or intolerable toxicity</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>FCR Arm</title>
            <description>Fludarabine, Cyclophosphamide, and Rituximab</description>
          </group>
          <group group_id="O2">
            <title>PCR Arm</title>
            <description>Pentostatin, Cyclophosphamide, and Rituximab</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Remission Rate (ORR)</title>
          <description>Complete remission (CR) see Outcome Measure 6. Partial remission (PR) must exhibit criteria 1 and 2 as well as one or more of the remaining features for at least 2 months.
≥50% decrease in peripheral blood lymphocyte count from the pretreatment baseline value.
≥50% reduction in lymphadenopathy.
≥50% reduction in the size of the liver and/or spleen.
Polymorphonuclear leukocytes ≥ 1,500/mm^3 or 50% improvement over baseline.
Platelets &gt;100,000/mm^3 or 50% improvement over baseline.
Hemoglobin &gt;11.0 g/dL or 50% improvement over baseline without transfusions. Nodular partial remission (nPR) is defined as a CR with persistent bone marrow nodules; Objective Remission (OR) = CR + PR + nPR.</description>
          <population>Per protocol population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.3" lower_limit="48.2" upper_limit="69.8"/>
                    <measurement group_id="O2" value="49.4" lower_limit="38.4" upper_limit="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) Rate at 1-year</title>
        <description>PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date</description>
        <time_frame>12 months after registered.</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>FCR Arm</title>
            <description>Fludarabine, Cyclophosphamide, and Rituximab</description>
          </group>
          <group group_id="O2">
            <title>PCR Arm</title>
            <description>Pentostatin, Cyclophosphamide, and Rituximab</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) Rate at 1-year</title>
          <description>PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date</description>
          <population>Per protocol population</population>
          <units>probability of Progression-free Survival</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" lower_limit="0.76" upper_limit="0.92"/>
                    <measurement group_id="O2" value="0.84" lower_limit="0.74" upper_limit="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) Rate at 2-year</title>
        <description>PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.</description>
        <time_frame>24 months after registered.</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>FCR Arm</title>
            <description>Fludarabine, Cyclophosphamide, and Rituximab</description>
          </group>
          <group group_id="O2">
            <title>PCR Arm</title>
            <description>Pentostatin, Cyclophosphamide, and Rituximab</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) Rate at 2-year</title>
          <description>PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.</description>
          <population>Per protocol population</population>
          <units>Probability of Progression-free Survival</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" lower_limit="0.60" upper_limit="0.81"/>
                    <measurement group_id="O2" value="0.63" lower_limit="0.51" upper_limit="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the whole treatment period, up to 30 days following last dose.</time_frame>
      <desc>The safety population, which received at least one of study treatment, was included in the analysis of adverse event. Patients included in this study were 88 and 89 in FCR arm and PCR arm, respectively.</desc>
      <group_list>
        <group group_id="E1">
          <title>FCR Arm</title>
          <description>Fludarabine, Cyclophosphamide, and Rituximab</description>
        </group>
        <group group_id="E2">
          <title>PCR Arm</title>
          <description>Pentostatin, Cyclophosphamide, and Rituximab</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>COSTART, CTCAE v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>EDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIOVASC DIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>HEART FAIL RIGHT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDO ENLARGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>DEHYDRAT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>PAIN ABDO</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>VOMIT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>CONFUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>FEVER</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>LIVER FAIL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERG REACT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>IMMUNOGLOBUL DEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>INFECT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ACIDOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MYASTHENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>TUMOR LYSIS SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>KIDNEY FAIL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH INC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>DYSPNEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>EDEMA LUNG</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>EFFUS PLEURAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>LUNG DIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>RESPIRAT DIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>COSTART, CTCAE v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" events="126" subjects_affected="45" subjects_at_risk="88"/>
                <counts group_id="E2" events="82" subjects_affected="34" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>EDEMA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" events="14" subjects_affected="8" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>EDEMA PERIPH</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="267" subjects_affected="41" subjects_at_risk="88"/>
                <counts group_id="E2" events="135" subjects_affected="34" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="271" subjects_affected="72" subjects_at_risk="88"/>
                <counts group_id="E2" events="185" subjects_affected="68" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="87" subjects_affected="33" subjects_at_risk="88"/>
                <counts group_id="E2" events="44" subjects_affected="24" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="88"/>
                <counts group_id="E2" events="31" subjects_affected="23" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>CONSTIP</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="88"/>
                <counts group_id="E2" events="16" subjects_affected="9" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>DEHYDRAT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="88"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="81" subjects_affected="47" subjects_at_risk="88"/>
                <counts group_id="E2" events="123" subjects_affected="49" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>PAIN ABDO</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="88"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>TASTE PERVERS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="88"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>VOMIT</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="88"/>
                <counts group_id="E2" events="44" subjects_affected="25" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="99" subjects_affected="48" subjects_at_risk="88"/>
                <counts group_id="E2" events="97" subjects_affected="53" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="88"/>
                <counts group_id="E2" events="25" subjects_affected="16" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>FEVER</sub_title>
                <counts group_id="E1" events="24" subjects_affected="18" subjects_at_risk="88"/>
                <counts group_id="E2" events="45" subjects_affected="30" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="88"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="88"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERG REACT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFECT</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>BILIRUBINEM</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>CREATININE INC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>HYPERGLYCEM</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>LDH INC</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>SGOT INC</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>SGPT INC</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="88"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>NEUROPATHY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>URIN FREQUENCY</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH INC</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="88"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>DYSPNEA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="88"/>
                <counts group_id="E2" events="20" subjects_affected="12" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>SKIN DRY</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Craig Reynolds</name_or_title>
      <organization>Ocala Oncology</organization>
      <phone>(352) 732-4032</phone>
      <email>Craig.Reynolds@USOncology.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

